{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:59:11Z","timestamp":1770411551163,"version":"3.49.0"},"reference-count":49,"publisher":"Wiley","issue":"11-12","license":[{"start":{"date-parts":[[2011,12,2]],"date-time":"2011-12-02T00:00:00Z","timestamp":1322784000000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:p>A new multi\u2010target approach based on liquid chromatography \u2013 electrospray ionization tandem mass spectrometry (LC\u2010(ESI)\u2010MS\/MS) is presented to screen for various classes of prohibited substances using direct injection of urine specimens. With a highly sensitive new generation hybrid mass spectrometer classic groups of drugs \u2013 for example, diuretics, beta2\u2010agonists \u2013 stimulants and narcotics are detectable at concentration levels far below the required limits.<\/jats:p><jats:p>Additionally, more challenging and various new target compounds could be implemented. Model compounds of stimulant conjugates were studied to investigate a possible screening without complex sample preparation. As a main achievement, the integration of the plasma volume expanders dextran and hydroxyethyl starch (HES), commonly analyzed in time\u2010consuming, stand\u2010alone procedures, is accomplished. To screen for relatively new prohibited compounds, a common metabolite of the selective androgen receptor modulator (SARMs) andarine, a metabolite of growth hormone releasing peptide (GHRP\u20102), and 5\u2010amino\u20104\u2010imidazolecarboxyamide ribonucleoside (AICAR) are analyzed. Following a completely new approach, conjugates of di(2\u2010ethylhexyl)\u2009phthalate (DEHP) metabolites are monitored to detect abnormally high levels of plasticizers indicating for illicit blood transfusion.<\/jats:p><jats:p>The assay was fully validated for qualitative purposes considering the parameters specificity, intra\u2010 (3.2\u201316.6%) and inter\u2010day precision (0.4\u201319.9%) at low, medium and high concentration, robustness, limit of detection (1\u201370\u2009ng\/ml, dextran: 30\u2009\u00b5g\/ml, HES: 10\u2009\u00b5g\/ml) and ion suppression\/enhancement effects.<\/jats:p><jats:p>The analyses of post\u2010administration and routine doping control samples demonstrates the applicability of the method for sports drug testing. This straightforward and reliable approach accomplishes the combination of different screening procedures resulting in a high\u2010throughput method that increases the efficiency of the labs daily work. Copyright \u00a9 2011 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/dta.372","type":"journal-article","created":{"date-parts":[[2011,12,3]],"date-time":"2011-12-03T06:58:21Z","timestamp":1322895501000},"page":"836-850","source":"Crossref","is-referenced-by-count":72,"title":["High\u2010throughput screening for various classes of doping agents using a new \u2018dilute\u2010and\u2010shoot\u2019 liquid chromatography\u2010tandem mass spectrometry multi\u2010target approach"],"prefix":"10.1002","volume":"3","author":[{"given":"S.","family":"Guddat","sequence":"first","affiliation":[{"name":"Institute of Biochemistry and Center for Preventive Doping Research German Sport University Cologne"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Solymos","sequence":"additional","affiliation":[{"name":"E\u00f6tv\u00f6s Lor\u00e1nd University Joint Research and Training Laboratory on Separation Techniques  Budapest Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Orlovius","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Center for Preventive Doping Research German Sport University Cologne"},{"name":"Pharmaceutical Institute, Pharmaceutical Chemistry I University of Bonn  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Center for Preventive Doping Research German Sport University Cologne"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Sigmund","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Center for Preventive Doping Research German Sport University Cologne"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Geyer","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Center for Preventive Doping Research German Sport University Cologne"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Thevis","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Center for Preventive Doping Research German Sport University Cologne"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Sch\u00e4nzer","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Center for Preventive Doping Research German Sport University Cologne"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,12,2]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(01)00058-5"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.201"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.166"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.09.036"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1255\/ejms.920"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.50"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.4554"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.4492"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.542"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1255\/ejms.925"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.3142"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/29.7.704"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.1219"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.986"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.1491"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2006.02.044"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.1436"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2009.03.033"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216\u2010011\u20104702\u20103"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.2389"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.509"},{"key":"e_1_2_7_23_1","unstructured":"WADA.2010 Minimum Required Performance Levels for Detection of Prohibited Substances WADA Technical Document TD2010MRPL. Available at:http:\/\/www.wada\u2010ama.org\/Documents\/World_Anti\u2010Doping_Program\/WADP\u2010IS\u2010Laboratories\/WADA_TD2010MRPLv1.0_Minimum%20Required%20Performance%20Levels_Sept%2001%202010_EN.pdf[15 June 2011]."},{"key":"e_1_2_7_24_1","unstructured":"ICH Harmonised Tripartite Guideline Validation of Analytical Procedures: Text and MethodologyQ2 (R1). Available at:www.ich.org\/LOB\/media\/MEDIA417.pdf[15 June2011]."},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1373\/49.7.1041"},{"key":"e_1_2_7_26_1","unstructured":"WADA.2010 Identification Criteria for Qualitative Assays Incorporating Column Chromatography and Mass Spectrometry WADA Technical Document TD2010IDCR. Available at:http:\/\/www.wada\u2010ama.org\/Documents\/World_Anti\u2010Doping_Program\/WADP\u2010IS\u2010Laboratories\/WADA_TD2010IDCRv1.0_Identification%20Criteria%20for%20Qualitative%20Assays_May%2008%202010_EN.doc.pdf[15 June 2011]."},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.06.051"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-010-3560-8"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.1584"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.4619"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02352.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-010-4589-4"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-003-0486-3"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/bms.1200180921"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)00251-6"},{"key":"e_1_2_7_36_1","unstructured":"World Anti\u2010Doping Agency. Available at:http:\/\/www.wada\u2010ama.org\/Documents\/World_Anti\u2010Doping_\u2010Program\/WADP\u2010Prohibited\u2010list\/WADA_Prohibited_List_2010_EN.pdf[14 January2010]."},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1255\/ejms.917"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.3247"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.1364"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-008-1882-6"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.3637"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1255\/ejms.924"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.1438"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.4637"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.017954"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470626634"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2005.10.014"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj1290011"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2008.11.001"},{"key":"e_1_2_7_50_1","unstructured":"WADA.2009 World Anti\u2010Doping Code International Standard for Laboratories version 6.0. Available at:http:\/\/www.wada\u2010ama.org[15 June 2011]."}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.372","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T15:23:52Z","timestamp":1760369032000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":49,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1002\/dta.372"],"URL":"https:\/\/doi.org\/10.1002\/dta.372","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}